BWXT Medical, Boston Scientific Reach Deal on Microsphere Manufacturing
BWXT Medical has entered into a long-term agreement to manufacture Boston Scientific’s TheraSphere Y-90 Glass Microspheres that are used for its hepatocellular carcinoma (HCC) treatment TheraSphere.
Under the agreement, BWXT Medical will invest in automating production of the microspheres at its Ottawa, Canada, facility.
The TheraSphere treatment uses millions of microscopic glass beads that contain radioactive yttrium-90, delivering them directly to liver tumors using a catheter. It recently received FDA premarket approval, making it the only radioembolization technology approved for treating unresectable HCC in the U.S.